CTI BioPharma Statistics
Total Valuation
CTI BioPharma has a market cap or net worth of $1.20 billion. The enterprise value is $1.26 billion.
Market Cap | 1.20B |
Enterprise Value | 1.26B |
Important Dates
The last earnings date was Monday, August 7, 2023, after market close.
Earnings Date | Aug 7, 2023 |
Ex-Dividend Date | n/a |
Share Statistics
CTI BioPharma has 131.88 million shares outstanding. The number of shares has increased by 31.78% in one year.
Current Share Class | n/a |
Shares Outstanding | 131.88M |
Shares Change (YoY) | +31.78% |
Shares Change (QoQ) | +2.32% |
Owned by Insiders (%) | 5.50% |
Owned by Institutions (%) | 83.29% |
Float | 99.89M |
Valuation Ratios
The trailing PE ratio is -16.23 and the forward PE ratio is -47.81.
PE Ratio | -16.23 |
Forward PE | -47.81 |
PS Ratio | 15.82 |
Forward PS | 8.75 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 16.58 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27
Current Ratio | 1.27 |
Quick Ratio | 1.20 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -3.54 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -55.80% |
Return on Capital (ROIC) | -44.80% |
Revenue Per Employee | $596,606 |
Profits Per Employee | -$545,189 |
Employee Count | 127 |
Asset Turnover | 0.61 |
Inventory Turnover | 10.15 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.19% in the last 52 weeks. The beta is 0.83, so CTI BioPharma's price volatility has been lower than the market average.
Beta (5Y) | 0.83 |
52-Week Price Change | +56.19% |
50-Day Moving Average | 7.53 |
200-Day Moving Average | 5.89 |
Relative Strength Index (RSI) | 83.62 |
Average Volume (20 Days) | 3,272,831 |
Short Selling Information
The latest short interest is 11.27 million, so 8.55% of the outstanding shares have been sold short.
Short Interest | 11.27M |
Short Previous Month | 8.08M |
Short % of Shares Out | 8.55% |
Short % of Float | 11.29% |
Short Ratio (days to cover) | 1.08 |
Income Statement
In the last 12 months, CTI BioPharma had revenue of $75.77 million and -$69.24 million in losses. Loss per share was -$0.56.
Revenue | 75.77M |
Gross Profit | 71.31M |
Operating Income | -53.93M |
Pretax Income | -69.24M |
Net Income | -69.24M |
EBITDA | -51.83M |
EBIT | -53.98M |
Loss Per Share | -$0.56 |
Balance Sheet
The company has $59.01 million in cash and $116.46 million in debt, giving a net cash position of -$57.44 million or -$0.44 per share.
Cash & Cash Equivalents | 59.01M |
Total Debt | 116.46M |
Net Cash | -57.44M |
Net Cash Per Share | -$0.44 |
Equity (Book Value) | -25.35M |
Book Value Per Share | -0.19 |
Working Capital | 18.23M |
Cash Flow
Operating Cash Flow | -82.32M |
Capital Expenditures | n/a |
Free Cash Flow | -82.32M |
FCF Per Share | -$0.63 |
Margins
Gross margin is 94.11%, with operating and profit margins of -71.18% and -91.38%.
Gross Margin | 94.11% |
Operating Margin | -71.18% |
Pretax Margin | -91.38% |
Profit Margin | -91.38% |
EBITDA Margin | -68.40% |
EBIT Margin | -71.24% |
FCF Margin | -108.64% |
Dividends & Yields
CTI BioPharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -31.78% |
Shareholder Yield | -31.78% |
Earnings Yield | -5.78% |
FCF Yield | -6.87% |
Analyst Forecast
The average price target for CTI BioPharma is $9.80, which is 7.81% higher than the current price. The consensus rating is "Buy".
Price Target | $9.80 |
Price Target Difference | 7.81% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | 59.31% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 3, 2017. It was a reverse split with a ratio of 1:10.
Last Split Date | Jan 3, 2017 |
Split Type | Reverse |
Split Ratio | 1:10 |
Scores
CTI BioPharma has an Altman Z-Score of -27.07 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -27.07 |
Piotroski F-Score | 3 |